General Information of Drug (ID: DM3X50C)

Drug Name
Benzyl-(2-phenyl-quinazolin-4-yl)-amine Drug Info
Synonyms
Benzyl-(2-phenyl-quinazolin-4-yl)-amine; N-Benzyl-2-phenyl-4-quinazolinamine; CHEMBL72650; N-benzyl-2-phenylquinazolin-4-amine; AC1LFMYC; BAS 01023367; Oprea1_781281; Oprea1_710967; MLS001210388; SCHEMBL1083763; MolPort-001-952-692; HMS2816J14; KUC104420N; ZINC274067; STL227888; BDBM50033296; KSC-1-145; benzyl(2-phenylquinazolin-4-yl)amine; AKOS000533392; MCULE-1161339740; SMR000515839
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
780643
TTD Drug ID
DM3X50C

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
DENBUFYLLINE DM2R15Q Cognitive impairment 6D71 Phase 3 [3]
SOTB07 DMIG4OX Asthma CA23 Phase 3 [4]
BI 1015550 DM6DO2P Idiopathic pulmonary fibrosis CB03.4 Phase 3 [5]
AN-2898 DMDK7CL Atopic dermatitis EA80 Phase 2 [6]
GPD-1116 DMOQ7YI Asthma CA23 Phase 2 [7]
TA-7906 DMZTAJL Atopic dermatitis EA80 Phase 2 [8]
HT-0712 DM2WP8F Cognitive impairment 6D71 Phase 2 [4]
TOFIMILAST DMLCUAS Chronic obstructive pulmonary disease CA22 Phase 2 [9]
AWD-12-281 DMVADGZ Rhinitis FA20 Phase 2 [10]
LIRIMILAST DMD4KAU Chronic obstructive pulmonary disease CA22 Phase 2 [9]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Dopamine transporter (DAT)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cocaine DMSOX7I Anaesthesia 9A78.6 Approved [11]
Dasotraline DMLDQFV Attention deficit hyperactivity disorder 6A05.Z Approved [12]
Methylphenidate DM7SJD6 Attention deficit hyperactivity disorder 6A05.Z Approved [13]
Modafinil DMYILBE Malignant glioma 2A00.0 Approved [14]
Phenmetrazine DMXYTN9 Obesity 5B81 Approved [15]
Ioflupane i-123 DMNARJT Parkinson disease 8A00.0 Approved [16]
DEXMETHYLPHENIDATE HYDROCHLORIDE DM8WBAH Attention deficit hyperactivity disorder 6A05.Z Approved [17]
Altropane DMO9WDS Attention deficit hyperactivity disorder 6A05.Z Approved [18]
Amitifadine DMS1X67 Obesity 5B81 Phase 3 [19]
NAV5001 DMRSI1M Dementia 6D80-6D86 Phase 3 [18]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dyphylline DM8DZC1 Acute bronchial asthma CA23 Approved [20]
Enprofylline DMFYZKN Asthma CA23 Approved [21]
DENBUFYLLINE DM2R15Q Cognitive impairment 6D71 Phase 3 [3]
SOTB07 DMIG4OX Asthma CA23 Phase 3 [22]
Tofisopam DMTGNWU Hyperuricaemia 5C55.Y Phase 2 [23]
AN-2898 DMDK7CL Atopic dermatitis EA80 Phase 2 [6]
GPD-1116 DMOQ7YI Asthma CA23 Phase 2 [7]
TA-7906 DMZTAJL Atopic dermatitis EA80 Phase 2 [8]
HT-0712 DM2WP8F Cognitive impairment 6D71 Phase 2 [22]
TOFIMILAST DMLCUAS Chronic obstructive pulmonary disease CA22 Phase 2 [24]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine transporter (DAT) TTVBI8W SC6A3_HUMAN Inhibitor [2]
Phosphodiesterase 4A (PDE4A) TTZ97H5 PDE4A_HUMAN Inhibitor [1]
Phosphodiesterase 4B (PDE4B) TTVIAT9 PDE4B_HUMAN Inhibitor [1]

References

1 Discovery of potent cyclic GMP phosphodiesterase inhibitors. 2-Pyridyl- and 2-imidazolylquinazolines possessing cyclic GMP phosphodiesterase and th... J Med Chem. 1995 Sep 1;38(18):3547-57.
2 Identification of a novel partial inhibitor of dopamine transporter among 4-substituted 2-phenylquinazolines. Bioorg Med Chem Lett. 2002 Aug 19;12(16):2225-8.
3 Pyrazolopyrimidine-2,4-dione sulfonamides: novel and selective calcitonin inducers. J Med Chem. 2002 May 23;45(11):2342-5.
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1301).
5 BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis. Front Pharmacol. 2022 Apr 20;13:838449.
6 An assessment of the genetic toxicology of novel boron-containing therapeutic agents. Environ Mol Mutagen. 2013 Jun;54(5):338-46.
7 Phosphodiesterase 4 inhibitor GPD-1116 markedly attenuates the development of cigarette smoke-induced emphysema in senescence-accelerated mice P1 s... Am J Physiol Lung Cell Mol Physiol. 2008 Feb;294(2):L196-204.
8 Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors. Clin Exp Immunol. 2002 Jun;128(3):460-6.
9 Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36.
10 The phosphodiesterase 4 inhibitor AWD 12-281 is active in a new guinea-pig model of allergic skin inflammation predictive of human skin penetration and suppresses both Th1 and Th2 cytokines in mice. J Pharm Pharmacol. 2005 Dec;57(12):1609-17.
11 Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
12 Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Neuropsychopharmacology. 2015 Nov;40(12):2745-52.
13 Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005 Jun 1;57(11):1410-5.
14 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
15 Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur J Pharmacol. 2002 Jun 28;447(1):51-7.
16 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
17 Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31.
18 Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse. 1998 Jun;29(2):128-41.
19 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 927).
20 Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. Eur J Pharmacol. 1994 Jun 2;258(1-2):85-94.
21 Effects of enprofylline, a new xanthine derivate, on human pregnant myometrium. Am J Obstet Gynecol. 1987 Apr;156(4):958-62.
22 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1300).
23 The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis. J Neural Transm (Vienna). 2010 Nov;117(11):1319-25.
24 GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization. J Pharmacol Exp Ther. 2011 Apr;337(1):145-54.